The results are EPIC1,2

Groundbreaking results of the EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history, are now published.

15-month delay

in time to composite primary endpoint compared with dogs receiving placebo*

60%more time

in asymptomatic Stage B2
of heart disease*

10% more life

without CHF signs that impact quality of life or
cardiac-related death†

PROVEN BENEFITS OF EARLY TREATMENT OF MYXOMATOUS MITRAL VALVE DISEASE (MMVD)—BEFORE CONGESTIVE HEART FAILURE (CHF)1

The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical MMVD—before the onset of CHF, cardiac-related death, or euthanasia (composite primary endpoint).

Heart icon
VIEW FINDINGS

WHAT DOES THE EPIC STUDY MEAN FOR VETERINARIANS?

Discover how veterinarians can apply the findings of the EPIC Study to their clinical practice.

Veterinarian icon
LEARN WHY THE EPIC STUDY IS SO IMPORTANT

HEAR FROM THE INVESTIGATORS

The EPIC Study represents a significant advancement in canine cardiology.
Watch the lead investigators discuss the implications of this groundbreaking study.

Prof. Adrian Boswood medium thumbnail image Assoc. Prof. Sonya Gordon medium thumbnail image Prof. Jens Häggström medium thumbnail image
WATCH NOW

WHAT DOES THE EPIC STUDY MEAN FOR DOGS AND THEIR OWNERS?

For pet owners, the EPIC Study results demonstrate how early treatment of MMVD can help dogs live longer, free from the symptoms of CHF.

slider.poodle-slite-alt
LEARN MORE

DIAGNOSING AND MANAGING PRECLINICAL MMVD

EPIC Study results can empower veterinarians to identify MMVD early and achieve better outcomes for their patients.

Echocardiography icon slider-icon-2-alt
LEARN MORE

DETAILS ABOUT THE EPIC STUDY

First published in 2016, the EPIC Study is the largest prospective,
randomised clinical study in veterinary cardiology history1

36 centres

centres

360 dogs

dogs

Double-blinded Placebo-controlled

double-blinded placebo-controlled

11 countries

countries

Over 5 years

years

GET THE STUDY RESULTS

2nd EPIC Study publication findings

Use of pimobendan significantly reduced heart size in dogs
with Stage B2 myxomatous mitral valve disease (MMVD)1,2

SIGNIFICANT CHANGE WITHIN 1 MONTH

SIGNIFICANT CHANGE WITHIN 1 MONTH

REDUCTION INHEART SIZE

REDUCTION IN
HEART SIZE

MORE TIME

MORE TIME

VIEW FINDINGS
NEW

Findings from the 3rd EPIC Study publication

In dogs with Stage B2 myxomatous mitral valve disease (MMVD), routine and frequent measuring of clinic respiratory rate and home resting respiratory rate may result
in earlier detection of congestive heart failure3

RESPIRATORY RATE (RR)

RESPIRATORY
RATE (RR)

Resting respiratory rate (RRR)

Resting respiratory
rate (RRR)

VIEW FINDINGS

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie Information
welcome to EPICtrial.com
Disclaimer

Are you a resident of the United States of America?

INFORMATION DISCUSSED ON EPICTRIAL.COM RELATES TO AN INDICATION THAT IS NOT REGISTERED IN THE USA.

You will now be redirected to a USA-specific website.